U.S. Sens. Roger Wicker (R-Mich.) and Sherrod Brown (D-Ohio) – the lead sponsors of the National Pediatric Research Network Act (NPRNA) – are introducing a new piece of legislation that will require the National Institutes of Health (NIH) to implement the law, according to FightSMA. The NPRNA was signed into…
News
Progress reports on six treatment options for spinal muscular atrophy (SMA), all currently in clinical trials, were spotlighted at the recent 2016 Annual SMA Conference in Anaheim, CA. The updates, provided by study representatives, shows that efforts are advancing toward new therapies for SMA. Four of the six treatment programs — AVXS-101, nusinersen, RG7800/RG7916, and…
Researchers at the National Tsing Hua University in Taiwan discovered seven new genes affecting severity and time of onset of spinal muscular atrophy (SMA). The finding offers researchers clues for what molecules to target in new drug development attempts. The study, “An Integrative Transcriptomic Analysis for Identifying…
The Spanish National Research Council (CSIC) recently unveiled a prototype of what it believes is the world’s first assistive exoskeleton designed to enhance mobility for children with the degenerative illness spinal muscular atrophy (SMA), a rare disease that affects 1 in 10,000 babies born in Spain. The 26-pound device, made primarily of…
Cure SMA recently granted a $304,000 drug discovery award to Livio Pellizzoni, assistant professor of Pathology & Cell Biology at Columbia University for a new research project with potential to treat spinal muscular atrophy (SMA). Pellizzoni and collaborators at Northwestern University have identified an altered cellular pathway in SMA patients, which may…
Cure SMA granted just over $2 million in new research funding in 2015-16. The non-profit organization dedicated to advocacy and treatment research funding for spinal muscular atrophy (SMA), reports that the SMA drug development spectrum has expanded dramatically over the past decade, with six of the 18 programs currently in…
Cure SMA, a non-profit organization dedicated in large part to funding research for the treatment and cure of spinal muscular atrophy, reports that its drug development pipeline has grown dramatically over the past decade. Of 18 programs currently in the pipeline, six are in clinical trials, several of them…
Cure SMA has just released an update on its spinal muscular atrophy (SMA) drug pipeline and, according to a press release, the latest version now includes increased coverage of potential treatment approaches to SMA: 18 active programs, 14 pharmaceutical partners, six programs in clinical trials, and 28 programs…
Biogen and Ionis Pharmaceuticals have recently issued several updates on the clinical development of nusinersen, an antisense drug designed to treat spinal muscular atrophy (SMA). The partners announced that the enrollment period is now completed for both Phase 3 trials and for the Phase 2 study. Phase 3 trials remain on…
FightSMA, an all-volunteer, parent-led nonprofit, reported that the U.S. Senate Appropriations Committee has, as part of the Fiscal Year 2017 Defense Appropriations bill, included for a first time spinal muscular atrophy (SMA) as a research topic in the Defense Department’s Peer-Reviewed Medical Research Program. FightSMA calls this welcome…
